4DMedical (4DX) Q1 2027 TU earnings summary

Executive summary

• Record Q1 FY27 activity: 119,672 scans, up 61% YoY, and 724 global sites, up 77% YoY; CT:VQ adoption expanded across the U.S., Europe and Australia.

• Unaudited operating revenue was $2.3m, up 66% YoY, with gross margins above 90%; quarter-end cash was $242.8m.

Financial highlights

• Q1 FY27 operating revenue of $2.3m, up 66% YoY, driven by CT:VQ adoption and increased scan volumes; gross margins remained above 90%.

• Customer receipts were $1.612m; net operating cash outflow was $15.174m, including $0.8m of one-off contextflow acquisition costs.

• Cash and cash equivalents declined from $277.954m to $242.763m during the quarter.

Outlook and guidance

• The major U.S. Veterans Affairs network agreement is expected to generate approximately US$800,000 over five years, with an initial one-year term and annual extensions.

• CLEAR recruitment and site activation tracked to plan, supporting a targeted CY2027 readout on CT:VQ in acute pulmonary embolism.

• Curagita-led German screening deployment covers approximately 25,000 procedures across 25 sites over three years.